Sector News

PharmStars announces “Digital Innovations in Therapeutic Delivery: Supply Chain to the Patient Interface” theme for its Fall 2023 Accelerator

July 2, 2023
Life sciences

PharmStars, the pharma-focused accelerator for digital health startups, is now accepting applications for its Fall 2023 cohort around the theme “Digital Innovations in Therapeutic Delivery: Supply Chain to the Patient Interface.” Startups with a digital product or prototype in the theme area are invited to apply by July 10, 2023.

The cohort is open to startups with digital health solutions that pharma can use to innovate therapeutic supply chain management, medication delivery, or the patient-drug experience for small molecules, biologics, or advanced therapies.

PharmStars seeks to bridge the “pharma-startup gap” by helping pharmaceutical firms and startups overcome cultural and other barriers to create productive partnerships, leading to greater success and faster adoption of digital solutions that improve patient outcomes. PharmStars’ unique PharmaU program provides education and intensive, personalized mentoring to help startups work more effectively with pharma.

“PharmStars is a fast-track MBA in pharma,” said Spring 2022 accelerator graduate David van Zuydam, CEO of Head Diagnostics (Dublin, Ireland).

PharmStars’ members will have priority access to the startups that complete the accelerator program. The program will culminate with a private Showcase Event in Boston in November 2023, at which each startup will present to and meet one-on-one with PharmStars’ pharma member companies.

“Our members have selected and shaped this cohort’s focus on the opportunity to innovate around the patient-drug interface. They are eager to work with startups with innovation in drug delivery platforms, medication supply chain efficiency and sustainability, and medication management,” said Naomi Fried, PharmStars’ founder and CEO.

The Fall 2023 program will be PharmStars’ fifth cohort. Forty-seven digital health startups have successfully graduated from the program since it launched in June 2021. Startups of all sizes have benefited from the program.

“Despite having collaborated with pharma companies for years, PharmaU was tremendously valuable to dive deep into the science and business of drug development, and has reframed our perspective on where and how we can add value and impact pharma,” explained Zainab Doctor, Vice President of Product at nference (Cambridge, MA) and Fall 2022 graduate.

Fall 2022 cohort graduate Sameer Sontakey, CEO of Biostrap (Los Angeles, CA), said, “Graduating from PharmStars has opened the door for us to so many great opportunities and partnerships, and we’re looking forward to continuing to build upon what we learned during those ten weeks!”

Applications for the Fall 2023 accelerator program and additional details are available now on the PharmStars’ website. PharmStars is also currently accepting a limited number of additional pharma and biotech members for 2023. Membership information can be found here.

About PharmStars
PharmStars is the member-based, pharma-focused accelerator for digital health startups. Through our extensive expertise across pharma, startups, digital health, and innovation, we understand the challenges that pharma and startups face when seeking to collaborate. Our PharmaU program supports digital health startups and our pharma members in “bridging the gap,” leading to greater success and faster patient adoption of “beyond the molecule” solutions.


comments closed

Related News

October 1, 2023

Clinical data from Boston Scientific and rivals could reshape pulmonary embolism market: analysts

Life sciences

After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.

October 1, 2023

AstraZeneca and SAS link up on AI and analytics

Life sciences

SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.

October 1, 2023

Will Big Pharma engage in Medicare price negotiations? Merck, AZ and BMS say they will

Life sciences

After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.

How can we help you?

We're easy to reach